A phase Ib/II clinical evaluation of Ponatinib in combination with 5- Azacitidine in patients failing prior therapy for FLT3-ITD positive acute myeloid leukaemia (AMLM21)

Trial Profile

A phase Ib/II clinical evaluation of Ponatinib in combination with 5- Azacitidine in patients failing prior therapy for FLT3-ITD positive acute myeloid leukaemia (AMLM21)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Azacitidine (Primary) ; Ponatinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PonAZA study
  • Most Recent Events

    • 11 Jul 2016 Planned number of patients changed from 93 to 60.
    • 11 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 22 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top